



Contact:

David Waldman or Justyna Gudaszewska
Crescendo Communications, LLC
Email: mmd@crescendo-ir.com
Tel: +48 693 354 580

Milestone Scientific Reports Independent Industry Coverage Following Successful FDA Marketing Clearance of the CompuFlo™ Epidural Instrument

LIVINGSTON, NJ, July 26, 2017 -- Milestone Medical Inc. (WAR:MMD) reported the following independent industry trade coverage following its recent FDA marketing clearance of the epidural instrument:

Publication: MobiHealthNews (Daily blog, 185,000 unique visitors/mo.)
Headline: Milestone Scientific's new FDA-cleared epidural instrument senses pressure
Article: <http://www.mobihealthnews.com/content/milestone-scientifics-new-fda-cleared-epidural-instrument-senses-pressure>

Publication: Medgadget (500,000 monthly page views)
Headline: CompuFlo Epidural Anesthesia System Measures Pressure at Needle's Tip, Cleared by FDA
Article: <https://www.medgadget.com/2017/07/compuFlo-epidural-anesthesia-system-measures-pressure-at-needles-tip-cleared-by-fda.html>

About Milestone Medical Inc.

Milestone Medical, Inc. has developed epidural and intra-articular drug delivery systems based on a patented, painless, computer-controlled injection and drug delivery technology originally developed by Milestone Scientific, Inc. Development of both the epidural and intra-articular instruments is now complete. The Company was granted the FDA marketing clearance of the epidural instrument in U.S. and is currently pursuing regulatory approval for intra-articular instrument in the U.S. Milestone Medical received CE Mark approval to sell and market its intra-articular and epidural instruments across European Union. For more information please visit www.medicalmilestone.com.

About Milestone Scientific Inc.

Milestone Scientific Inc. (MLSS) is a leading medical research and development company that designs and patents innovative injection technologies. Milestone's computer-controlled systems are designed to make injections precise, efficient, and virtually painless. For more information please visit our website: www.milestonescientific.com.

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future

business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2016. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.